Inefficient Cytotoxic T Lymphocyte–Mediated Killing of HIV-1–Infected Cells In Vivo by Asquith, Becca et al.
 
Inefficient Cytotoxic T Lymphocyte–Mediated Killing of HIV-
1–Infected Cells In Vivo
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Asquith, Becca, Charles T. T. Edwards, Marc Lipsitch, and
Angela R. McLean. 2006. Inefficient cytotoxic T
lymphocyte–mediated killing of HIV-1–infected cells in vivo.
PLoS Biology 4(4): e90.
Published Version doi:10.1371/journal.pbio.0040090
Accessed February 19, 2015 1:19:34 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4593277
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAInefficient Cytotoxic T Lymphocyte–
Mediated Killing of HIV-1–Infected Cells
In Vivo
Becca Asquith
1,2*, Charles T. T. Edwards
3, Marc Lipsitch
4, Angela R. McLean
1
1 Department of Zoology, University of Oxford, Oxford, United Kingdom, 2 Department of Immunology, Imperial College London, London, United Kingdom, 3 Nuffield
Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom, 4 Departments of Epidemiology and Immunology & Infectious Diseases, Harvard School of
Public Health, Boston, Massachusetts, United States of America
Understanding the role of cytotoxic T lymphocytes (CTLs) in controlling HIV-1 infection is vital for vaccine design.
However, it is difficult to assess the importance of CTLs in natural infection. Different human leukocyte antigen (HLA)
class I alleles are associated with different rates of progression to AIDS, indicating that CTLs play a protective role. Yet
virus clearance rates following antiretroviral therapy are not impaired in individuals with advanced HIV disease,
suggesting that weakening of the CTL response is not the major underlying cause of disease progression and that CTLs
do not have an important protective role. Here we reconcile these apparently conflicting studies. We estimate the
selection pressure exerted by CTL responses that drive the emergence of immune escape variants, thereby directly
quantifying the efficiency of HIV-1–specific CTLs in vivo. We estimate that only 2% of productively infected CD4
þ cell
death is attributable to CTLs recognising a single epitope. We suggest that CTLs kill a large number of infected cells
(about 10
7) per day but are not responsible for the majority of infected cell death.
Citation: Asquith B, Edwards CTT, Lipsitch M, McLean AR (2006) Inefficient cytotoxic T lymphocyte–mediated killing of HIV-1–infected cells in vivo. PLoS Biol 4(4): e90.
Introduction
Half of all CD4
þ T cells that are productively infected with
HIV-1 die every 12 h. A productively infected cell is estimated
to have a lifespan of about 1 d [1–5], considerably less than
the lifespan of CD4
þ cells in uninfected individuals [6]. It is
not known whether the majority of this cell death is caused by
cytotoxic T lymphocyte (CTL)–mediated cytotoxicity or other
mechanisms such as viral cytopathicity, activation-induced
apoptosis, or complement-mediated lysis.
There is good evidence that the CTL response contributes
to the control of HIV-1 infection in vivo [7–11]. However, the
magnitude of this contribution is contentious [2,3,12–16].
One of the best pieces of evidence that CTLs exert selective
pressure on HIV-1 is the existence of CTL escape mutations.
However, these data have never been rigorously quantiﬁed.
Indeed, it has been argued that CTL escape is a relatively
infrequent event, with most CTL clones remaining stable for
long periods of time, suggesting either considerable ﬁtness
constraints on HIV mutations or weak CTL selection pressure
for escape [17]. New data on the in vivo ﬁtness cost of escape
variants have recently become available [18–21]. These new
data allow analysis of the rate of outgrowth of CTL escape
variants that yields estimates of the selective pressure exerted
by a single CTL response against HIV-1 in vivo.
The rate at which an escape variant replaces the wild-type,
‘‘the rate of escape,’’ is determined by the balance between
the efﬁciency of the CTL clone(s) evaded and the ﬁtness cost
of the mutations (Figure 1). The aim of this work was to
estimate the efﬁciency of a single HIV-1–speciﬁc CTL
response, i.e., the infected cell death rate in vivo attributable
to CTL clones recognising one epitope. This was done by
quantifying the rate of escape and the ﬁtness cost of CTL
escape variants. By comparing the CTL-mediated death rate
with the total death rate of HIV-infected cells, the proportion
of infected cell death attributable to the CTL response was
estimated.
Results
We estimated the rate of escape of 21 reported CTL escape
variants using longitudinal data from 12 HIV-1–infected
individuals [9,10,19,22–28] (Table 1). In every case we made a
‘‘best estimate’’ of the rate of escape by ﬁtting a simple model
to the data (Equation 2 in Materials and Methods). Where
possible we also made an ‘‘optimistic estimate,’’ which can be
considered to be an approximate upper bound on the rate of
escape. The ﬁts of the model to the data are shown in Figure 2
and the estimates of the rate of escape are shown in Figure 3
and Table 2. The results were remarkably consistent from one
escape variant to the next: in 20 of 21 datasets the rate of
escape was less than 0.1 d
 1. The median rate of escape was
0.01 d
 1, and taking the most optimistic interpretation, the
median rate of escape was 0.04 d
 1.
It is possible that, as the proportion of cells infected with
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PLoS BIOLOGYwild-type virus declines, the antigenic stimulus declines,
causing a loss of epitope-speciﬁc CTLs. This would reduce
the selection pressure for escape and so would lead to an
underestimate of the escape rate that would be observed
under continuing CTL pressure. In fact, in the majority of
cases where CTL frequency was measured the magnitude of
the response to the epitope of interest was reported to be
fairly stable through time. However, there were cases where
the CTL response did decline or else was not measured, so we
quantiﬁed the impact of a declining CTL response on the
escape-rate estimates. This was done by estimating the half-
life of HIV-1–speciﬁc CTLs following highly active antire-
troviral treatment (HAART) and then assuming that CTLs
declined with the same half-life during outgrowth of the
variant (see Materials and Methods). Even using this ex-
tremely stringent assumption (antigenic stimulus falls con-
siderably more rapidly on commencing HAART than during
escape [1,4,8]) the median escape rate was still only 0.055 d
 1.
To see if this low rate of escape could be explained by a
high ﬁtness cost of CTL escape variants we quantiﬁed the rate
of reversion of escape variants to wild-type on transmission
to individuals who did not possess the human leukocyte
antigen (HLA) allele necessary to bind the epitope of interest.
We quantiﬁed the rate of reversion in seven datasets from ﬁve
patients [18–21] (Table 3). The ﬁts of the model to the data
are shown in Figure 4 and the estimates of the rate of
reversion in Figure 5 and Table 4. This analysis showed that
the ﬁtness cost of an average CTL escape mutation was very
low—about 0.005 d
 1. While these low ﬁtness costs were
surprising, they are consistent with data from in vitro
competition assays [18] and accumulation of escape muta-
tions in the population over time [18,21,29], which both
suggest that the ﬁtness cost of some escape variants is close to
zero.
Given that escape and reversion rates are consistent across
individuals it is reasonable to consider the average rate of
escape and reversion of a CTL escape variant. Putting these
average estimates together we can estimate the rate of lysis of
infected cells by a single CTL response. We found that the
rate of lysis was about 0.02 d
 1 (escape rateþreversion rate¼
0.01þ0.005 d
 1) and was at most 0.06 d
 1 (0.055 þ0.005 d
 1).
This implies that, using the best estimate, an infected cell that
was subject only to lysis by CTLs speciﬁc for one epitope
would live for about 50 days. A productively infected cell has
a lifespan of about 1 d [1–5]; therefore, only about 2% of
productively infected cell death is attributable to CTL
responses against a single epitope.
On comparing the rate of CTL lysis in individuals with
primary and chronic infection we found that the rate of CTL
lysis was signiﬁcantly faster during primary infection than in
chronic infection (p ¼ 0.004 Wilcoxon–Mann-Whitney two-
tailed test, Figure 6).
Discussion
HIV-1–speciﬁc CTLs have two known main modes of
action: direct killing of infected cells and secretion of soluble
antiviral factors. Unless secretion of antiviral factors is highly
localised and directed, CTL escape will only reﬂect escape
from CTL-mediated killing since the action of antiviral
factors is nonspeciﬁc and would therefore give no advantage
to escape variants. Our study of the role of CTLs therefore
only relates to CTL killing and will not encompass CTL
secretion of antiviral factors which may be of considerable
signiﬁcance [11,15].
It would be fascinating to extrapolate these results on the
rate of lysis by a single CTL response to estimate the total
Figure 1. Calculating the Rate of CTL Killing
We need to know how important CTLs are in the control of HIV-1
infection, but it is not possible to measure the rate at which CTLs kill HIV-
1–infected cells in vivo using conventional assays. Here we develop an
alternative approach. CTL selection pressure drives viral escape, so a
surrogate marker of the importance of CTLs is the rate at which CTL
escape variants replace the wild-type. (A) In a host bearing the restricting
HLA allele a CTL escape variant grows more rapidly than and replaces the
wild-type because it is subject to a lower rate of CTL killing. The rate of
replacement of the wild-type by the escape variant, ‘‘the escape rate,’’ is
equal to the difference in growth rate of the wild-type and escape variant.
If everything else were equal, the difference in growth rate would be
equal to the difference in the CTL killing rate of the wild-type and the
escape variant. This would mean that the CTL pressure on the specific
epitope that has undergone mutation (the ‘‘escape epitope’’) could be
measuredby the escape rate.However,everythingelse is notequal. Many
escape variants will carry a fitness cost, which will slow the growth rate of
the escape variant and thus decrease the escape rate. This fitness cost is
revealed as the reversion rate when the variant is transferred to a host
who does not bear the restricting HLA (B). The escape rate will therefore
be equal to the rate of lysis by CTLs targeting the escape epitope minus
the fitness cost. Expressed in a different way, the rate of lysis of HIV-1–
infected cells by CTLs targeting the escape epitope is equal to the escape
rate plus the reversion rate. In (A) the relative position of the two lines
‘‘strong CTL pressure, high fitness cost’’ and ‘‘weak CTL pressure, low
fitness cost’’ could be interchanged depending on the magnitude of the
differences in CTL strength and variant fitness.
DOI: 10.1371/journal.pbio.0040090.g001
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Inefficient CTL Killing in HIV Infectionextent of CTL-mediated killing. However, to do this it is
necessary to know how many of the CTL responses naturally
present during HIV-1 infection are of sufﬁcient strength to
drive escape. In most but not all reports of CTL escape, the
immune response selecting for the variant was immunodo-
minant, suggesting that only a few oligoclonal CTL responses
are of sufﬁcient strength to drive escape [24,30,31]. The
available literature [19,22,24] suggests that an average
individual makes at most 5 CTL responses of such strength
(see Materials and Methods). If these ﬁve CTL responses are
responsible for the majority of CTL lysis then this yields an
infected cell death rate of about 0.1 d
 1—a tenth of the total
infected cell death observed. However, this estimate neglects
lysis by the potentially large number of CTL responses of
insufﬁcient strength to drive escape. Comprehensive epitope
analysis puts the average number of CTL responses in an
infected individual at between 14 [32] and 19 [33]. Including
lysis by all of these responses increases the proportion of
infected cell death attributable to the CTL response to about
20% (see Materials and Methods). So we suggest that although
CTL-mediated lysis plays an important role in controlling
HIV-1 infection (killing approximately 10%–20% of produc-
tively infected CD4
þ cells every day), CTLs may not be
responsible for the majority of infected cell death. This
conclusion, like all scientiﬁc conclusions, may change with
the advent of new data but it is also consistent with reports of
bystander apoptosis [34] and chronic activation-induced cell
death [35,36], which indicate that there is considerable CD4
þ
cell death that cannot be directly attributed to HIV-1–speciﬁc
CTL-mediated lysis.
Our estimate of the rate of HIV-1–speciﬁc CTL lysis
totalled across all CTL responses of 0.1 to 0.2 d
 1 is
considerably lower than in vitro estimates (1 d
 1 [37,38]),
possibly reﬂecting the artiﬁcial nature of experiments in
which a high density of peptide-pulsed B cells or transformed
CD4
þ cells infected with a high multiplicity of infection are
exposed to CD8
þ cells in a homogenous environment. Our
estimates are also lower than rates of CTL lysis calculated
(albeit using very different methods) for other virus in-
fections which range from 1 d
 1 for HTLV-I to 12 d
 1 for
acute LCMV [39–42]. Why CTLs kill HIV-infected cells so
slowly is not clear. HIV-1–speciﬁc CTLs have an unusual
phenotype and are low in perforin [15,16,43], and it has been
suggested that progressive loss of CD4
þ cell help may be
important. Consistent with this, we found that the rate of
CTL lysis was signiﬁcantly faster during primary infection
than in chronic infection, implying a signiﬁcant weakening of
single CTL responses with long-term infection.
The conclusion that CTL may not be responsible for the
majority of infected cell death uniﬁes apparently contra-
dictory results indicating that there is an association between
HLA class I type and rate of progression to AIDS despite a
lack of association between disease stage and infected cell
clearance rate following therapy [2,3]. Infected cell clearance
rates are not reduced in subjects with advanced disease; this
has been used as an argument that weakening of the CTL
response does not accompany disease progression and that
Table 1. Escape Datasets Studied
Dataset Data
Source
Class I HLA Type Disease
Stage
Viral Load
(Copies/ml)
CD4 Count
(Cells/mm
3)
CTL Epitope (HXB2)
AB
1 [27] 0201 Primary 30,000 1,000 Gag p17 77–85
2 [28] 01 03 2705 35 Primary 1,258,925 520 Gag p24 131–140
3 [28] 02 22 2705 35 Asymptomatic — 330 Gag p24 131–140
4 [23] 27 Late stage — 250 Gag p24 131–140
5 [9] 01 29 08 44 Primary 146,800 748 Env gp160 31–39
6 [19] 0101 0301 0801 0801 Primary 34,293 490 Gag p17 20–28 and 24–31
7 [19] 0101 0301 0801 0801 Primary 34,293 490 Gag p17 18–26
8 [19] 0101 0301 0801 0801 Primary 34,293 490 Nef 73–82
9 [10] 08 Asymptomatic — 400 Gag p17 21–35
10 [26] 01 01 07 08 Primary 7,600,000 384 Nef 90–97
11 [25] 03 Asymptomatic 10,000
a 450 Nef 73–82
12 [22] 03 32 51 15 Asymptomatic 400 900 Env gp41 190–208
13 [22] 03 32 51 15 Asymptomatic 400 1,200 Nef 120–128
14 [22] 03 32 51 15 Asymptomatic 200 1,100 Pol-RT 128–135
15 [24] 2902 1402 Primary 0
b — Env gp160 209–217
16 [24] 2902 1402 Primary 70
b — Env gp41 73–81
17 [24] 2902 1402 Primary 0
b — Gag p17 119–127
18 [24] 2902 1402 Primary 75
b — Tat 24–32
19 [24] 2902 0801 4403 Primary 34,700 972 Env gp160 209–217
20 [24] 2902 0801 4403 Primary 216,400 358 Tat 24–32
21 [24] 1103 2402 1402 1501 Primary 1,000,000 900 Tat 32–41, Tat 36–45, and Tat 39–47
Disease stage (as reported at start of sampling period): primary denotes primary infection and seroconversion, before viral set point was attained; asymptomatic denotes asymptomatic
infection (including persistent generalised lympadenopathy); and late stage denotes late-stage infection, CD4 count ,200/mm
3.
Viral load and CD4 count are at the start of the sampling period (or where this is not available at the nearest time point).
CTL epitope position is numbered with respect to the HXB2 reference strain.
aEscape 11 viral load units are copies per 10
6 CD4
þ cells.
bEscape 15–18 viral load units are p24 antigen in pg/ml.
— denotes not reported.
DOI: 10.1371/journal.pbio.0040090.t001
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Inefficient CTL Killing in HIV InfectionCTLs do not play an important protective role. We resolve
this issue by suggesting that CTL lysis is small relative to other
factors contributing to infected cell death, and therefore
between-individual differences in CTL lysis rates (e.g., with
disease stage) are unlikely to be detectable by measuring total
infected cell clearance rates (see Materials and Methods).
However, as we have shown, these small differences can be
detected if the death rate attributable to CTLs is measured
directly (Figure 6). Furthermore, these small differences in
CTL lysis rate translate into large differences in terms of the
absolute number of productively infected cells killed, and are
likely to be clinically relevant. For example, a difference in
lysis rate of 0.1 d
 1 is equivalent to a difference of about 10
7
productively infected cells killed each day, every day, for
several years. Such a large, cumulative difference could well
alter the timing of disease progression.
This work has implications for vaccines designed to induce
a lytic CTL response. One of the aims of therapeutic, and
possibly prophylactic vaccines, is to boost the chronic
memory response, so it becomes important to understand
why the HIV-1–speciﬁc CTL response weakens with time.
Furthermore, if it is true that the CTL response kills a
minority of infected cells but that this is sufﬁcient to affect
clinical outcome, this suggests that, unless the CTL response
elicited by vaccines is several-fold more efﬁcient than the
natural response, vaccines relying on the lytic pathway are
unlikely to prevent infection or to mediate complete viral
clearance, but that they may well reduce viral load and
lengthen the asymptomatic period.
Materials and Methods
Model of infected cell dynamics. Initially it was assumed that
productively infected cell dynamics follow ﬁrst-order kinetics, as
detailed observation of both viral clearance and viral rebound have
indicated that this is most appropriate. Later, we relaxed this
assumption. Here we refer to the epitope that is no longer recognised
due to mutation as the ‘‘escape epitope.’’ CD4
þ cells productively
infected with wild-type virus (y) replicate at a rate a (net of all factors
except CTL-mediated death), are killed by CTLs recognising epitopes
other than the escape epitope at a rate b and are killed by CTLs
recognising the escape epitope at a rate c. CD4
þ cells productively
infected with a CTL escape variant (x) replicate at a rate a9 (net of all
factors except CTL-mediated death) and are killed by CTLs
recognising epitopes other than escape epitope at a rate b. Infected
cell dynamics are therefore represented by
˙ y ¼ ay   by   cy wild   type
˙ x ¼ a9x   bx variant ð1Þ
In a host able to mount the relevant CTL responses (i.e., with the
restricting HLA allele), the selective advantage of the escape variant
(i.e., the rate of escape) is the difference in growth rate between the
escape variant and the wild-type k ¼ a9   b   (a   b   c) ¼ c   a þ a9.
Many escape mutations will carry a ﬁtness cost that partially offsets
the ‘‘beneﬁt’’ to the virus of evading the CTL response. This ﬁtness
cost will be the difference in replication rate between the escape
variant and the wild-type u¼a a9.I fu is greater than zero then the
mutation has a deleterious effect on viral replication (in the absence
of a CTL response).
Quantiﬁcation of the rate of escape (k). The rate of escape (i.e., the
rate of outgrowth of a CTL escape variant compared to the wild-type
[escape variant growth rate wild-type growth rate]) is determined by
the balance between the rate of lysis evaded (c) and the ﬁtness cost of
Figure 2. Escape Data and Theoretical Fits
Fit of the model to the experimental data for each of the 21 escape datasets. Best (filled squares) and optimistic (open circles) data and the fit of the
model (solid line and dashed line, respectively) to the data. Best estimates of the escape rate of a variant were obtained by fitting the model to the
published data. Maximal, ‘‘optimistic’’ estimates of CTL efficiency were also made by omitting data or including mutations that have not been shown to
confer escape (e.g., in the case of fluctuating variant frequencies rather than steady outgrowth a more optimistic estimate can often be obtained if some
later data are discarded, e.g., Escape 9). These maximal estimates are less accurate but they provide an approximate upper bound on the rate of escape.
DOI: 10.1371/journal.pbio.0040090.g002
Figure 3. Escape Rate Estimates
Best (filled diamonds) and optimistic (filled squares) estimates of the rate
of escape in each of the 21 datasets. Best estimates are shown 61
standard error.
DOI: 10.1371/journal.pbio.0040090.g003
Table 2. Estimates of the Rate of Escape
Dataset
Best
Estimate (d
 1)
Standard
Error
Optimistic Estimate
(d
 1)
1 0.006 0.001 0.008
2 0.002 0.003 0.040
3 0.001 0.003 0.015
4 0.010 0.011 0.019
5 0.048 0.022 0.053
6 0.032 0.008 ND
7 0.002 0.006 ND
8 0.022 0.013 0.050
9  0.001 0.003 0.085
10 0.049 0.012 ND
11 0.003 0.003 0.011
12 0.005 0.001 ND
13 0.002 0.001 0.012
14 0.012 0.000 ND
15 0.072 0.041 0.130
16 0.023 0.016 ND
17 0.119 0.021 ND
18 0.047 0.054 0.051
19 0.041 0.005 ND
20 0.006 0.004 0.013
21 0.066 0.032 0.189
Median 0.01 — 0.04
The best estimate of the escape rate was obtained by fitting a simple model to the
longitudinal escape data using nonlinear least-squares regression. An ‘‘optimistic’’
estimate of the escape rate was made where possible; this can be considered as an
approximate upper bound on the rate of escape. Optimistic estimates were often made
by omitting later data points; for this reason it was not possible to estimate the standard
error for these estimates.
ND, not done (no plausible alternative assumptions giving a more optimistic estimate).
DOI: 10.1371/journal.pbio.0040090.t002
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estimated from longitudinal escape data. If p(t) is the proportion of
viral sequences that have escape mutations in the epitope of interest
at time t then solving Equation 1 we have
pðtÞ¼
xðtÞ
yðtÞþxðtÞ
¼
1
ge kt þ 1
ð2Þ
where g ¼ y(0)/x(0) and k ¼ c   u.
This model was ﬁt to longitudinal escape data using nonlinear
least-squares regression (Levenberg-Marquardt method) and the rate
of escape of the variant (k ¼ c   u) estimated. The standard error of
the escape rate was estimated using the asymptotic covariance matrix
method.
Quantiﬁcation of the ﬁtness cost of escape variants (u ¼ a   a9). If
an escape variant is transmitted to an individual who does not have
the HLA class I allele to bind the peptide in which the escape
mutation has arisen then the selection pressure for the escape
mutation will be lost. Both the wild-type and the variant will face the
same CTL response, and their relative dynamics will be determined
by the difference in their replication rates (u ¼ a   a9). If the escape
mutation carried a ﬁtness cost then the virus will tend to revert to
wild-type. If the mutation was cost neutral then it will tend to be
stable over time. The proportion of viral sequences with an escape
mutation will still be described by Equation 2 but now there is no
CTL response against the escape epitope, so c¼0. By ﬁtting the model
(Equation 2) with c ¼ 0 to longitudinal reversion data the ﬁtness cost
of the escape mutation, u ¼ a   a9, can be estimated.
Estimate of the average rate of killing of productively infected cells
by a CTL response against a single epitope (c). The average rate of
escape (k ¼ c   u) of a CTL escape variant was estimated from
longitudinal escape data. The average ﬁtness cost (u¼a a9) of a CTL
escape variant was estimated from reversion data. Putting these two
estimates together we quantiﬁed c ¼ k þ u the average rate of killing
(per day) of productively infected cells by a CTL response against a
single epitope. High levels of multiple infection and recombination
[44] ensure that, in cases of simultaneous escape at multiple epitopes,
escape at one epitope is independent of escape at another.
Estimate of the average rate of killing of productively infected cells
per CTL. We have estimated that a single CTL response kills
productively infected cells at a rate of 0.02 d
 1. This is an estimate of
the cumulative impact of all CD8
þ cells recognising that epitope.
Many mathematical models express the killing rate of infected cells in
units of killing per day per epitope-speciﬁc CD8
þcell we therefore re-
expressed our estimate in these units to facilitate future development
of these models.
In 13 of the escape datasets the proportion of peripheral blood
mononuclear cells (PBMCs) responding to the escape epitope was
measured by IFNc ELIspot. In a further two datasets the proportion
of CD8
þ cells able to bind the escape epitope–presenting allele
complex was quantiﬁed by major histocompatibility class I tetramer;
this ﬁgure was converted to the proportion of PBMCs able to bind the
escape epitope–presenting allele complex assuming 15% of PBMCs
are CD8
þ (A. Mosley, personal communication). Using these 15
estimates of speciﬁc CD8
þ cell frequency in PBMCs (median 0.1%)
and an estimate of the number of PBMCs in the body of 1.4 3 1012
[45] we estimated the average rate of killing was 3310
 11 per day per
epitope-speciﬁc CD8
þ cell, considerably smaller than the CTL killing
rate used in many models [46,47].
Datasets. The rate of escape was quantiﬁed in 21 datasets from 12
HIV-1–infected subjects (Table 1). The rate of reversion was
quantiﬁed in seven datasets from ﬁve individuals (Table 3).
The best estimate of the rate of escape (k) was obtained by ﬁtting
the model (Equation 2) to the escape data. To estimate the maximal
possible efﬁciency of the CTL response against a particular epitope,
‘‘optimistic’’ estimates were also made where possible. These
estimates are less accurate than the best estimates because they
involve omitting data or including mutations that have not been
shown to confer escape (e.g. in the case of ﬂuctuating variant
frequencies rather than steady outgrowth a more optimistic estimate
of k can often be obtained if some later data is discarded), but they
provide an approximate upper bound on the possible rate of escape.
The assumptions made to obtain an optimistic estimate are listed in
Supporting Information. For the reversion data optimistic estimates
of the rate of reversion were not made because the data were more
straightforward—monotonic reversion of a single escape mutation—
allowing little scope for alternative assumptions.
To make reliable estimates of the escape rate it was necessary to
have at least two data points that were not zero (no escape variants
detected) or one (no wild-type sequence detected). All datasets found
that matched these criteria were analysed and the results reported
here. However, this raised the possibility that faster rates of escape
not captured by infrequent sampling protocols were omitted. To
avoid this possible bias we also analysed all datasets reporting CTL
escape regardless of the number of data points available. The escape
rates estimated from these datasets (median k ¼ 0.01 d
 1) were very
similar to those obtained from the full datasets. More importantly
there were only ten such datasets (compared to 21 full datasets)
despite there being a higher probability of observing them (given
equal occurrence), suggesting that the majority of CTL escape is not
happening on a much faster scale than that implied by our analysis of
the full datasets.
In ﬁve of the 21 datasets, sequences were obtained from proviral
DNA rather than from viral RNA. There was no signiﬁcant difference
between the rate of escape calculated using DNA and RNA (p ¼ 0.11,
two-tailed Wilcoxon–Mann-Whitney). In ﬁve of the 21 datasets the
escape variant was capable of eliciting a partial CTL response in vitro.
There was a possibility that incomplete escape would lead to an
underestimate of the rate of CTL lysis of infected cells. We took two
approaches to quantifying the impact of incomplete escape. First, we
simply removed the ﬁve cases where escape was incomplete. This
yielded a median rate of lysis of 0.013 d
 1. Alternatively, we estimated
the ‘‘escapedness’’ of the variant in each of the 21 cases considered
and adjusted our estimate of the rate of lysis by this factor.
Escapedness was deﬁned as the percentage of the CTL response
escaped, so an escapedness of 100% means escape was complete. The
median escapedness was 100%; the mean was approximately 85%.
Clearly, adjusting by the median escapedness does not change our
Table 3. Reversion Datasets Studied
Dataset Data
Source
HLA Class I Type Disease
Stage
Viral Load
(Copies/ml)
CD4 Count
(Cells/mm
3)
CTL Epitope
(HXB2)
AB
1 [18] 07 07 Primary — — Gag p24 15–23
2 [20] 07 07 Primary — — Gag p24 108–117
3 [20] 07 07 Primary — — Gag p24 108–117
4 [20] 07 44 Primary — — Gag p24 108–117
5 [19] 0201 3101 3501 3905 Primary 500,000 250 Gag p17 18–26
6 [21] 02 26 51 62 Asymptomatic 13,000 543 Nef 134–143
7 [21] 02 02 39 60 Asymptomatic 72,000 378 Nef 134–143
Disease stage (as reported at start of sampling period): primary denotes primary infection and seroconversion, before viral set point was attained; asymptomatic denotes asymptomatic
infection (including persistent generalised lympadenopathy). Viral load and CD4 count are at the start of the sampling period (or where this is not available at the nearest time point).
CTL epitope position is numbered with respect to the HXB2 reference strain.
— denotes not reported.
DOI: 10.1371/journal.pbio.0040090.t003
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Inefficient CTL Killing in HIV Infectionestimate of the rate of CTL lysis; adjusting by the mean changes it to
(0.01þ0.005)/0.85¼0.02 d
 1. Whichever approach is taken, it is clear
that incomplete escape has very little impact on our estimate of the
rate of CTL lysis (previously 0.015 d
 1). Furthermore, the escape rate
of the ﬁve cases where escape was incomplete was not signiﬁcantly
different from the escape rate of the remaining 16, where escape was
between 90%–100% (p ¼ 0.4, two-tailed Wilcoxon–Mann-Whitney).
One possible explanation for the absence of an association between a
slow rate of escape and incomplete escape is that during the in vitro
test for escapedness, when very high levels of peptide are added
exogenously (often to professional antigen-presenting cells), it is
possible to elicit a partial response to a variant that is a genuine
complete escape variant in vivo [23].
Quantifying the impact of CTL decline. There is a possibility that
as wild-type virus is replaced by the variant the CTL response to the
wild-type will decline due to loss of antigen stimulation. This would
lead to a reduction in the selection pressure for escape and an
underestimate of the escape rate in the presence of continuous
selection pressure.
To assess the impact on the estimated rate of escape of a possible
decline in the epitope-speciﬁc CTL response the model (Equation 1)
was adjusted to allow for an exponentially declining CTL response
instead of a constant CTL response. So Equation 1 was rewritten as
˙ y ¼ ay   by   ce mty wild   type
˙ x ¼ a9x   bx variant ð3Þ
where a, a9,b ,and c are as before and m is the rate of loss of CTL
recognising the epitope in which escape has occurred. So now in
Equation 2 g is as before, i.e., g¼y(0)/x(0), but k is changed to k¼c(1 
e
 mt)/(mt)   u.
The rate of CTL decline (m) was estimated using the rate of HIV-1–
speciﬁc CTL decline following HAART. Four estimates of the rate of
CTL decline have been made: m ¼ 0.0002, 0.002, 0.003, and 0.015 d
 1
[8,48–50]. We used both the mean (m ¼ 0.005 d
 1) and the maximum
(m ¼ 0.015 d
 1). Following successful HAART viral load falls rapidly
and dramatically, by two or more orders of magnitude in a few days
[1,4,8]. The loss of antigenic stimulus on commencing HAART is
therefore much greater than during CTL escape. Consequently, the
estimates of the rate of CTL decline we have used are likely to be too
large. These very stringent assumptions mean that the estimates of
the escape rate obtained using the model (Equation 3) should be
considered to be overestimates. Using m¼0.005 d
 1 we found that the
median rate of escape was 0.055 d 1. Using m ¼ 0.015 d
 1 we found
that the median rate of escape was 0.086 d 1. In the latter case it was
difﬁcult to ﬁt the model (Equation 3) to the escape data, suggesting
that the assumptions were too stringent.
Impact of between-individual variation in CTL lysis rate. Following
antiretroviral treatment the rate of viral clearance is very consistent
between individuals and there is no correlation with disease stage [2–
4]. This would seem to imply that differences in the rate of CTL
killing are not important predictors of disease progression [38].
However, if the rate of CTL killing is small relative to other factors
contributing to the overall rate of viral clearance, it might be very
difﬁcult to detect variations in the rate of CTL killing. We have
calculated that an average total CTL response kills 10% of
productively infected cells per day (lysis rate ¼ 0.1 d
 1). We wished
to know if between-individual differences in this lysis rate would be
manifest in virus clearance estimates.
As an extreme example we considered an individual with a very
poor CTL response that is unable to kill any infected cells (total
lysis rate ¼ 0d
 1) and an individual with an average CTL response
(total lysis rate ¼ 0.1 d
 1). This between-individual difference in
CTL lysis would lead to a difference in infected cell clearance
following HAART of 0.1 d
 1. A between-individual difference of 0.1
d
 1 is well within the range of variation observed (about 0.3–0.7 d
 1
[4]), despite this range being considered far too small to
accommodate between-individual variation in the CTL response
[38]. Even the most thorough analysis [4] of very frequent samples
(only achieved in a few individuals) yields estimates of the infected
cell clearance rate with 95% conﬁdence bounds that are typically
60.08 d
 1. This raises the possibility that, even in the most
favourable experimental settings, it would be difﬁcult to detect
even the considerable difference between the very weak and
average CTL responder considered here. It is therefore not
surprising that less accurate methods have failed to detect an
association between infected cell clearance rate and disease stage
(CD4
þ cell count) of the patient.
The difference between the weak responder and the average
responder considered here is equivalent to a difference of about
107 productively infected cells killed every day (10% of the
productively infected cell pool, which is estimated to contain about
10
8 cells [51]).
Estimating the proportion of productively infected cell death
attributable to the total CTL response. We have quantiﬁed the rate of
lysis of productively infected cells by a single CTL response (i.e., CTL
clone[s] targeting one epitope). To make an order of magnitude
approximation of the total extent of CTL lysis we needed to estimate
how many CTL responses of sufﬁcient strength to drive escape were
naturally present during HIV-1 infection. In most, but not all reports
of CTL escape, the immune response selecting for the variant was
immunodominant, suggesting that only a few oligoclonal CTL
responses were able to drive escape [24,30,31]. Three papers
Figure 4. Reversion Data and Theoretical Fits
Fit of the model (solid line) to the experimental data (filled square) for each of the seven reversion datasets.
DOI: 10.1371/journal.pbio.0040090.g004
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strength to drive escape at any one time. This was done by
sequencing either all or the majority of viral genes at multiple time
points and looking for evidence of CTL escape. Between them, these
three papers studied nine individuals and it was found that,
averaging over time, the median number of CTL responses of
sufﬁcient strength to drive selection of an escape variant was two
(range, zero to ﬁve). Although a large number of epitopes were
analysed, only one study (Geels et al. [22], who found three such CTL
responses) analysed the whole genome (the rest studied three to four
genes), so it was a possibility that these ﬁgures underestimated the
number of CTL responses present at any one time. We therefore
erred on the side of the importance of CTL and used a higher
estimate of ﬁve CTL responses of sufﬁcient strength to drive escape.
If these ﬁve responses accounted for the majority of CTL lysis then
the infected cell death attributable to the total CTL response was
about 5 30.02 ¼ 0.1 d
 1, i.e., a tenth of the productively infected cell
death observed. However, this neglected CTL responses below the
‘‘threshold of detection’’ of our method. It has been found [32,33]
that an average HIV-1–infected individual mounts CTL responses
against 14–19 epitopes, suggesting that on average nine to 14 CTL
responses are below the threshold of detection (too inefﬁcient to
drive escape). We wished to estimate the maximum possible
contribution to infected cell lysis of these weaker responses by
estimating the threshold of detection of our method. From Table 2 it
can be seen that the threshold was about 0.002 d
 1 (two responses
weaker than this were measured but they appeared to be artiﬁcially
deﬂated by reversion of the variant to wild-type). From Table 4 it can
be seen that the average ﬁtness cost was 0.005 d
 1. The nine to 14
inefﬁcient responses were therefore estimated to have an efﬁciency
of 0.002 þ 0.005 ¼ 0.007 d
 1 or less. So the maximum rate of lysis of
productively infected cells was 530.02þ930.007 to 530.02þ143
0.007¼ 0.16 to 0.20 d
 1; i.e., accounting for the extra inefﬁcient CTL
responses increased the proportion of productively infected cell
death attributable to the CTL response to about 20%. In order for
50% of productively infected cell death to be attributable to the CTL
response it would be necessary to have 60 CTL responses at the
detection threshold (in addition to the ﬁve above the detection
threshold). Even if we considered an extremely strong immune
response in which all 14–19 responses were of sufﬁcient strength to
drive CTL escape, then the proportion of infected cells killed was still
only between 28% and 38% (0.02 3 14, 0.02 3 19). It is thought that
CTL responses driving escape are of average strength or higher. If
CTL responses driving escape were atypically weak (i.e., weaker than
the average CTL response) then this calculation would tend to
underestimate the importance of CTL.
Robustness of results to model changes. In the basic model
(Equation 1) and consequently in the solution (Equation 2) we have
assumed that both viral clearance and viral production follow ﬁrst-
order kinetics, i.e., that infected cells die at a constant rate and grow
at a constant rate. Following HAART viral load declines exponen-
tially for at least three orders of magnitude [4]. Furthermore, ex vivo
studies have indicated that CTL lysis causes an exponential decrease
of infected cells [52]. This suggests that viral clearance follows ﬁrst
order kinetics. Changes to this assumption have already been
considered above. Similarly, during viral rebound (on stopping
HAART or developing drug resistance mutations), viral load rises
exponentially for three, sometime four orders of magnitude [53],
indicating that viral production also follows ﬁrst order kinetics.
Table 4. Estimates of the Rate of Reversion
Dataset Best Estimate (d
 1) Standard Error
1  0.005 0.000
2 0.016 0.007
3 0.000 0.000
4 0.005 0.001
5 0.000 0.000
6  0.014 —
7 0.005 0.000
Median 0.005
The best estimate of the reversion rate was obtained by fitting a simple model to the
longitudinal reversion data using nonlinear least-squares regression. Optimistic estimates
of the reversion rates were not made as the data were more straightforward—monotonic
reversion of a single escape variant—allowing little scope for alternative assumptions.
— denotes insufficient data to estimate the standard error.
DOI: 10.1371/journal.pbio.0040090.t004
Figure 5. Reversion Rate Estimates
Best (filled diamonds) estimates of the reversion rate in each of the seven
datasets. Best estimates are shown 61 standard error. Escape and
reversion may require additional compensatory mutations which will
limit the occurrence of escape or reversion and will delay the time until
escape or reversion occurs. The effect of such compensatory mutations
(even if they occur outside of the epitope) will be fully quantified
because their effect will be reflected in the rate of escape/reversion of
the variant. It is also possible that compensatory mutations will be
acquired after the wild-type has been completely replaced by the escape
variant. Interestingly, escape 7 and reversion 5 are ‘‘paired.’’ That is, the
outgrowth of the escape variant labeled 7 was observed in one
individual (the ‘‘donor’’) who transmitted the escape variant to their
sexual partner (the ‘‘recipient’’), and in whom the escape variant then
reverted (reversion 5). Outgrowth of the escape variant was observed in
the donor during the time at which the recipient was infected. Both the
escape and reversion rates are typical and lie within the range of the
other observed escape/reversion rates, implying that low reversion rates
cannot be attributed to the accumulation of compensatory mutations
following escape.
DOI: 10.1371/journal.pbio.0040090.g005
Figure 6. The Rate of CTL Killing Is Significantly Lower in Individuals with
Long-Term Infection
Individuals with chronic infection (filled circles) have weaker single CTL
responses than individuals with primary infection (filled squares). The
median rate of lysis of productively infected cells was 0.008 d
 1 in
chronic infection and 0.04 d
 1 in primary infection. The rate of CTL lysis
was significantly lower in individuals with long-term infection (Wilcoxon–
Mann-Whitney p ¼ 0.004 two-tailed). Chronic infection was defined as
infection in which the viral set point has been attained; primary infection
as early infection prior to stabilisation of viral load which will include
both seropositive and seronegative individuals.
DOI: 10.1371/journal.pbio.0040090.g006
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is high, it could be argued that target cell limitation becomes
important. This will not alter our results, as target cell limitation will
act to decrease the growth rate of escape variants and wild-type virus
equally, and we are only interested in the difference between these
growth rates.
An alternative method of calculating the optimistic estimate was
also performed for each of the 21 escape datasets. The rate of escape
was calculated from the greatest rate of change in frequency of the
variant (between two time points) in the dataset. This was done by
ﬁtting a straight line to the transformed data ln(1/p 1) where p is the
frequency of the escape variant. ln(1/p 1) is ill-deﬁned for p¼0 or p¼
1 so, where the frequency of the variant was 0/n this was
approximated by 1/n þ 1 and where the frequency was n/n this was
approximated by n/n þ 1. The median rate of escape using this
method was 0.05 d
 1, which was very close to the median optimistic
estimate (0.04 d
 1). In cases where the CTL selection pressure for
escape declines with time, either due to loss of the CTL response
against the wild-type epitope or due to emergence of a new CTL
response to the escape variant (when mutation has reduced T cell
receptor recognition rather than MHC binding), it would be expected
that initial rapid escape would be slowed or even reversed at later
time points. This alternative method of calculating the optimistic
estimate will reﬂect the most rapid period of escape and will not be
inﬂuenced by later reduced selection pressure. Estimates made using
this method can therefore be considered to be alternatives to the best
estimates with correction for CTL decline or to the optimistic
estimates.
Statistical analysis. The rate of CTL killing in primary infection
(n ¼ 14) was compared with the rate of CTL killing in chronic
infection (n ¼ 7) using the nonparametric exact Wilcoxon–Mann-
Whitney two-tailed test.
Supporting Information
Protocol S1. Fit of Model to the Data
Found at DOI: 10.1371/journal.pbio.0040090.sd001 (66 KB DOC).
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